WO2005021012A1 - ゲムシタビン封入薬剤担体 - Google Patents
ゲムシタビン封入薬剤担体 Download PDFInfo
- Publication number
- WO2005021012A1 WO2005021012A1 PCT/JP2004/012871 JP2004012871W WO2005021012A1 WO 2005021012 A1 WO2005021012 A1 WO 2005021012A1 JP 2004012871 W JP2004012871 W JP 2004012871W WO 2005021012 A1 WO2005021012 A1 WO 2005021012A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- lipid
- drug carrier
- gemushi
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a drug carrier encapsulating gemushi bin and / or a salt thereof. Background art.
- DDS drug delivery systems
- a drug carrier for DDS a method of using closed vesicles such as ribosomes, emulsions, lipid microspheres, nanoparticles, etc., and encapsulating the drug IJ in the closed vesicles, or polymer synthetic polymer micelles / polysaccharides, etc.
- closed vesicles such as ribosomes, emulsions, lipid microspheres, nanoparticles, etc.
- encapsulating the drug IJ in the closed vesicles or polymer synthetic polymer micelles / polysaccharides, etc.
- macromolecular carriers such as antibodies and proteins or specific Methods for surface modification with low molecular weight functional molecules such as sugar chains and peptides have been studied.
- the problem of highly selective delivery of a drug to a cell or a cell can be solved by modifying the drug carrier with a hydrophilic polymer.
- closed vesicles in particular, target tissues for aggregation by interaction with opsonin proteins and plasma proteins in blood, or for trapping in reticuloendothelial tissues (RES) such as liver and spleen.
- RES reticuloendothelial tissues
- closed vesicles and polymer carriers In contrast to the difficulties in delivering highly selective delivery to cells and cells, by coating the surfaces of these closed vesicles and polymer carriers with hydrophilic polymers such as polyethylene glycol (PEG), It has been possible to increase the stability in the blood by preventing adsorption of proteins and opsonin proteins, etc., and to avoid trapping by RES ("LIPOSOMES from Physics to Appli cat ions” Elsevier, DD Las ic (1993)). By being coated with a hydrophilic polymer in this manner, closed vesicles such as liposomes can have high blood retention, and are therefore passive when vascular permeability of tumor tissue or inflammatory sites is enhanced. To be integrated.
- hydrophilic polymers such as polyethylene glycol (PEG)
- drugs are administered intravenously or subcutaneously. There is the fact that the later half-life is as short as a few hours.
- These drugs are useful in controlled release formulations that can be used to deliver therapeutic concentrations of the drug, and one approach to this is the entrapment in ribosomes.
- the antimetabolite cytosine arabinoside also known as
- VPG liposomal gel
- the rate of release of the drug from the inside of the liposome to the outside by diffusion can be suppressed by making the concentration of the drug inside and outside the ribosome the same, but the drug outside the ribosome rapidly increases after administration.
- Spreads in blood. The drug concentration, which controlled the release rate, could not be maintained and the drug from the liposome Rapid diffusion has occurred and the fundamental solution of slowing the release rate in the blood has not been reached. Disclosure of the invention
- an object of the present invention is to provide a gemushi evening bottle-enclosed drug carrier that can suppress the release rate of gemushi evening bottle and maintain the local concentration of gemushi evening bottle for a long period of time. The above problem is solved by the present invention described below.
- a carrier formed of a membrane wherein the lipid component constituting the membrane is a carrier containing cholesterol at a ratio of 0 to 35 mo 1% or less together with phosphorus moon substance and gemushi bin and A drug carrier encapsulating Z or a salt thereof.
- the polyethylene dalicol derivative is preferably a lipid derivative of polyethylene dalicol.
- the molecular weight of the polyethylene glycol moiety is usually on the order of 500 to 10,000.
- Preferable examples of the charged substance include cationized lipids.
- the drug carrier according to any one of the above (1) to (6), wherein the drug carrier further contains at least one selected from the group consisting of a stabilizer and an antioxidant.
- a method for preventing and / or treating a disease comprising administering to a host a prophylactically and / or therapeutically effective amount of the pharmaceutical carrier of any one of (1) to (7).
- a method for releasing an effective amount of gemushibin and Z or a salt thereof in a host comprising administering the drug carrier according to any one of (1) to (7) to the host.
- FIG. 1 shows liposomes containing gemushi hydrochloride bottles obtained in Example 1 and Comparative Example 1.
- FIG. 3 is a graph showing the stability in the 3 buffer solutions by gemushi hydrochloride release rate.
- Figure 2 shows the stability of the liposomes obtained in Example 1 and Comparative Example 1 in a buffer at 37 ° C in the presence of 10% fetal serum containing gemushi-bin hydrochloride. It is a figure shown by a release rate.
- FIG. 3 is a graph showing the stability of the liposome encapsulated in gemushi evening bottle obtained in Examples 2 to 3 and Comparative Examples 2 to 3 in a buffer at 37 ° C. in terms of the release rate of gemushi evening bottle. It is.
- FIG. 4 is a graph showing the stability of the ribosome encapsulating gemshibin hydrochloride obtained in Example 4 and Comparative Example 4 in a buffer at 37 ° C. in terms of the release rate of gemshibin hydrochloride.
- Figure 5 shows the stability of the liposomes encapsulating gemshibin hydrochloride obtained in Example 4 and Comparative Example 4 in a buffer at 37 ° C in the presence of 10% fetal serum at 37 ° C.
- FIG. 4 is a graph showing the stability of the ribosome encapsulating gemshibin hydrochloride obtained in Example 4 and Comparative Example 4 in a buffer at 37 ° C. in terms of the release rate of gemshibin hydrochloride.
- Figure 5 shows the stability of the liposomes encapsulating gemshibin hydrochloride obtained in Example 4 and Comparative Example 4 in a buffer at 37 ° C in the presence of 10% fetal serum at 37 ° C.
- FIG. 4 is a graph showing
- FIG. 6 is a graph showing the concentration of gemushi-uvine hydrochloride in plasma at the blood collection time after intravenously injecting ribosomes containing gemushi-uvine hydrochloride obtained in Example 5 and Comparative Example 5 into mice.
- FIG. 7 is a graph showing the concentration of gemcitine hydrochloride in plasma during the blood collection time after intravenously injecting the liposomes containing gemcitine hydrochloride obtained in Example 6 into mice.
- the present invention relates to a carrier comprising a membrane basically composed of phospholipids and cholesterols contained in a specific ratio within a predetermined range.
- a salt-encapsulated drug carrier is provided.
- Gemcitabine is a highly specific deoxycytidine derivative with antimetabolic activity.
- gemushibin of CAS No.95058-81-4 (Chemical name (Sat) -2'-Doxy-2 ', 2'-difluorocytidine (C 9 H 11 F 2 N 3 0 . 4 molecular weight 263.20), and CASNo.122111-03- 9 of Gemushi evening bottle hydrochloride (gemc itabine ⁇ HC 1) is (molecular weight 299.66) in the present invention, as Gemushi evening bottle, usually Gemushi evening bottle: 3 ⁇ 4 salt (Hereinafter, this may be referred to as gem-sulfate hydrochloride.).
- “Gemushi evening bottle and Z or ⁇ J thereof” may be simply referred to as “Gemushi evening bottle” or “drug”.
- the main membrane material of the carrier for encapsulating gemushibin is desirably one having the ability to form closed vesicles, and phospholipids are selected.
- the main membrane material is a component having the highest content among the constituent components of the lipid membrane.
- Phospholipids are the main constituents of biological membranes, and are amphiphilic substances that have a group of hydrophobic groups composed of long-chain alkyl groups and hydrophilic groups composed of phosphate groups in the molecule. .
- Phospholipids include phospholipids and derivatives thereof, and are not particularly limited.
- phosphatidylcholine lecithin
- phosphadylglycerol phosphatidic acid
- distearoylphosphatidylcholine-- Distearoyl Phosphatidylcholine DSPC
- dipalmitoyl phosphatidylcholine DP PC
- dimyristoyl phosphatidylcholine DMPC
- EPC egg yolk phosphatidylcholine
- phosphatidylethanolamine phosphatidylserine
- phosphatid Natural or synthetic phospholipids such as diluinositol, sphingomyelin, and cardiolipin, or those obtained by hydrogenating these in a conventional manner, such as hydrogenated soybean phosphatidylcholine (HSPC), hydrogenated egg yolk lecithin ( HEP C).
- HSPC hydrogenated soybean phosphatidylcholine
- the lipid component forming the carrier membrane contains a specific ratio of cholesterols together with the above phospholipids.
- cholesterols are cholesterol or derivatives thereof, and are sterols having a cyclopentanohydrophenanthrene ring.
- Specific examples of cholesterols include, but are not particularly limited to, cholesterol and cholestanol.
- the lipid membrane may contain a plurality of different cholesterols as cholesterols, or may contain a single cholesterol. Is also good.
- Phospholipids and cholesterols are components of lipid bilayers (membranes) that form drug carriers as closed vesicles.
- the above “the amount of the lipid component j constituting the membrane of the carrier” is the total amount of the lipid, and does not include a lipid surface modifier.
- the cationizing agent described below when contained in the membrane component (that is, in the case of a force-theonized lipid membrane), phospholipids, cholesterols,
- the term "total lipid” is used, including cationized lipids.
- the below-described PEG derivatives eg, PEG-PE are not included in the total lipids.
- the lipid bilayer may contain one or more substances other than phospholipids and cholesterols.
- the other substance to be contained in the membrane is not particularly limited as long as it can exert the effects of the present invention, but is not limited to phospholipids in consideration of its safety, stability in a living body, and the like. Examples include lipids and surface modifiers.
- Lipids other than phospholipids are lipids and derivatives thereof that have a hydrophobic group composed of a long-chain alkyl group or the like in the molecule and do not contain a phosphate group in the molecule, and are not particularly limited. Glycetoglycolipids, glycosphingolipids and the like can be mentioned.
- the surface modifier include, but are not particularly limited to, a charged substance, a hydrophilic polymer, and a derivative of a water-soluble polysaccharide such as dalc acid, sialic acid, and dextran. 12871
- positively charged substances include stearylamine and WO97 / 4166 (which are incorporated herein by reference).
- Disclosed amidines include, for example, basic substances such as 3,5-dipentyl dimethylbenzidine, and basic amino acid surfactants such as N-acyl-arginine. '
- Examples of the negatively charged substance include fatty acids such as oleic acid and stearic acid, gangliosides having sialic acid such as gandarioside GM 1 and gandarioside GM 3, and acidic amino acid surfactants such as N-acyl-glutamine.
- fatty acids such as oleic acid and stearic acid
- gangliosides having sialic acid such as gandarioside GM 1 and gandarioside GM 3
- acidic amino acid surfactants such as N-acyl-glutamine.
- hydrophilic polymer examples include, but are not limited to, polyethylene glycol (PEG), dexton, pullulan, ficoll, polyvinyl alcohol, styrene-maleic anhydride alternating copolymer, and divinyl ether-maleic anhydride alternating copolymer. , Synthetic polyamino acids, amylose, amylopectin, chitosan, mannan, cyclodextrin, pectin, carrageenan and the like. Among them, polyethylene glycol is preferable because it has an effect of improving blood retention.
- hydrophilic polymer In order for the hydrophilic polymer to be present on the surface of the drug carrier, a derivative in which the above-mentioned hydrophilic polymer is combined with the hydrophobic compound can be used.
- a hydrophobic compound site is stably present in a state of being inserted into a hydrophobic lipid membrane. Along with this, the hydrophilic polymer site is stabilized on the carrier surface (outside).
- the hydrophobic conjugate include, but are not particularly limited to, long-chain aliphatic alcohols, sterols, polyoxypropylene alkyls, and dariserin fatty acid esters.
- Derivatives obtained by combining a hydrophilic polymer and a hydrophobic compound include PEG derivatives, and are not particularly limited, but polyethylene glycol-phosphatidyl Ethanolamine (PEG-PE) is exemplified.
- the molecular weight of PEG constituting the PEG derivative is not particularly limited, but is generally about 500 to 10,000, preferably 1,000 to 7,000, more preferably 1> 00 to 5,000. is there.
- the PEG derivative in the carrier can be present in a ratio of usually 0 to 20 mol%, preferably 0.1 to 1 mol, more preferably 0.1 to 5 mol, still more preferably 0.1 to 1 mol of the total lipid. Is 0.5-5mo 1%.
- the carrier can take various forms as long as it can enclose gemushi bottle.
- the term “encapsulation” refers to a state in which the drug (gemushi bottle) is enclosed in a closed space of a carrier formed of a lipid membrane, and a part or all of the drug is included in a lipid layer constituting the membrane. This means that the drug is rarely supported, or that the drug is attached to and supported on the outer surface of the carrier.
- Particularly preferred carriers are closed vesicles having a structure that forms a space separated from the outside by a membrane generated based on the polarities of the hydrophobic group and the hydrophilic group of the membrane component. is there.
- Ribosomes are closed vesicles composed of a phospholipid-based bilayer.
- the shape of the carrier can be spherical or similar.
- the size of the particle diameter is not particularly limited, but is 0.02 to 250 m, preferably 0.03 to 0.4 m. And more preferably 0.05 to 0.2 m (50 to 200 nm).
- the drug carrier of the present invention may further contain a pharmaceutically acceptable stabilizer and Z or an antioxidant depending on the administration route.
- the stabilizer include, but are not particularly limited to, saccharides such as glycerol and sucrose.
- the antioxidant include, but are not limited to, ascorbic acid, uric acid, and tocopherol homologs such as vitamin E. Tocopherol has four isomers of, ⁇ ,, and ⁇ , and any of them can be used in the present invention.
- the drug carrier of the present invention may further contain a pharmaceutically acceptable additive depending on the administration route.
- a pharmaceutically acceptable additive include: physiological saline, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, lipoxyvinyl polymer, sodium carboxymethylcell, polyacryl.
- the additives are appropriately selected from the above depending on the dosage form, or are used in combination, but are not limited thereto.
- the drug carrier in an aspect containing these additives can be provided as a pharmaceutical composition.
- the pharmaceutical composition of the present invention can be prepared by a usual method, for example, refrigeration at 0 to 8 ° C. Can be saved.
- the drug carrier of the present invention can be obtained by a conventional method.
- a method for producing liposomes is described below, but is not limited thereto.
- the phospholipids and cholesterols and, if necessary, the membrane constituents of other carriers are mixed with an organic solvent such as chloroform, and the organic solvent is distilled off. Form a thin film.
- a drug is added to the flask and stirred vigorously to obtain a ribosome dispersion.
- the drug carrier can be obtained as a dispersion by centrifuging the obtained ribosome dispersion, decanting the supernatant and removing the drug that has not been encapsulated.
- ribosomes can also be obtained by mixing the above components and discharging the mixture under high pressure by a high-pressure discharge emulsifier (Terada, Yoshimura et al., “Liposom J Springer in Life Sciences” Fairlark Tokyo (1992))
- the pH gradient method can be used to encapsulate the drug in the carrier (Liposome Technology Liposome Preparation and Related Techniques, edited by G. Gregoriadis, 2nd edition, Vol. 1-III, CRC Press).
- a drug carrier containing a substance in which PEG-PE is bound to a lipid membrane in a lipid bilayer can be obtained by the following method, but is not limited thereto.
- the liposome-forming lipid and PEG-PE may be mixed in advance to form a liposome, and the liposome-forming lipid may be mixed with a ribosome-forming lipid that does not contain PEG-PE. After forming a liposome by a conventional method using a lipid, PEG-PE may be added.
- the drug carrier of the present invention can be purified by a commonly used method such as gel filtration, dialysis, membrane separation, and centrifugation to remove the drug not encapsulated in the drug carrier.
- the drug carrier is provided through a step for removing unencapsulated drug. Therefore, a concentration gradient of the drug may occur between the inside of the drug carrier and the outside of the drug carrier via the lipid bilayer (membrane).
- the drug carrier of the present invention has no drug that is not encapsulated in the lipid bilayer outside of the lipid bilayer after preparation. Then, the drug enclosed in the drug carrier is released from the inside to the outside environment.
- the “encapsulation rate” refers to the composition of the carrier mixed with gemushibin and Z or its salt to form a drug carrier encapsulating it, and encapsulating the carrier with respect to the mixed drug (amount charged).
- the drug carrier of the present invention reaches the target site with the drug encapsulated, and consequently delivers the drug to be encapsulated to the target site. Delivery of a drug to a target site may be by allowing the drug encapsulated in the carrier to be taken into the target site, or by exerting the effect of the drug on or near the target site without being taken into the target site. It may be.
- the term “release” means that a drug encapsulated in a drug carrier passes through a lipid membrane constituting the drug carrier or changes in a part of the structure of the lipid membrane, thereby causing the outside of the closed vesicle to change. Means coming out.
- Release rate refers to the ratio of the drug (exported by weight) to the drug that comes out of the closed vesicle from the drug carrier containing the components of the carrier and gemushibin and / or its salt, and the drug encapsulated in the carrier. Or mo 1 ratio). 4 012871
- Low release rate means that a small amount of drug comes out of the closed vesicles per unit time.
- the drug carrier of the present invention exhibits a favorable release rate by containing cholesterol in a specific ratio as a membrane component.
- the release rate can be calculated by sedimenting the drug carrier of the present invention by centrifugation and measuring the amount of drug present in the supernatant and the drug carrier.
- retention in blood means a property of a host administered with a drug carrier, in which the drug encapsulated in the carrier is present in the blood. As soon as the drug is released from the carrier, it disappears from the blood and acts on the exposed site. Good retention in the blood allows for the administration of smaller doses of the drug.
- the drug carrier of the present invention exhibits favorable blood retention properties by containing cholesterols in a specific ratio as membrane constituents.
- the “target site” is a specific site where a drug (gemushi evening bottle) encapsulated in a drug carrier is released and acts, and cells, tissues, organs or organs specified for each site and their Mean inside.
- Target sites such as cells, yarns, organs or organs and their interiors, can be sites for treatment with a drug, and exert their effects upon exposure to the released drug.
- the target site in the present invention is not particularly limited, but includes a tumor.
- the tumor to be treated is not particularly limited, but is a solid tumor. 2004/012871
- Target sites include tumor cells, tissues, organs or organs and their interiors. Therefore, in the present invention, the disease means the above-mentioned tumor, and the drug is expected to exhibit an antitumor effect against them.
- exposure means that the drug released outside the drug carrier has an effect on the external environment. Specifically, the released drug (gemushi evening bottle) exerts its antitumor effect by approaching and contacting the target site. By acting on the target site, the drug locally acts on cells in the cell cycle in which DNA synthesis at the target site is performed, and exhibits the expected effect. In order to exhibit such effects, it is necessary to balance the release rate of the drug from the drug carrier with the blood retention of the drug carrier.
- the drug carrier of the present invention releases gemushibin and / or a salt thereof at a preferred release rate and is used to expose a desired target site. Therefore, in the present invention, by administering an effective amount of a gemushi bin and a drug carrier encapsulating Z or a salt thereof to the host, an effective amount of the gemushi in the host for prevention and / or treatment of the disease in the host.
- Parenteral systemic or local administration to the host (patient) to release the evening bottle and / or its salt or to expose an effective amount of gemushi evening bottle and Z or its salt to the target site Can be.
- Hosts to be administered include mammals, preferably humans, monkeys, rats, livestock, and the like.
- Parenteral administration routes include intravenous injection (intravenous injection) such as infusion, intramuscular injection, intraperitoneal injection, and subcutaneous injection.
- intravenous injection such as infusion, intramuscular injection, intraperitoneal injection, and subcutaneous injection.
- the appropriate administration method is selected according to the patient's age and symptoms. be able to.
- the drug carrier of the present invention already suffers from diseases Administered to a patient in an amount sufficient to cure or at least partially arrest the symptoms of the disease.
- the effective dose of the drug encapsulated in the drug carrier is selected from the range of 0.1 to 10 Omg / kg of body weight per day.
- the drug carrier of the present invention is not limited to these dosages.
- the administration may be performed after the onset of the disease, or when the onset of the disease is predicted, may be administered prophylactically to alleviate the symptoms at the onset.
- the administration period can be selected according to the patient's age and symptoms.
- the pharmaceutical composition can be administered by syringe IV.
- a catheter is inserted into the body of a patient or a host, for example, into a lumen, for example, into a blood vessel, and the tip is guided to the vicinity of a target site.
- the catheter is passed through the catheter to a desired target site or its vicinity or a target site. It is also possible to administer from the site where blood flow is expected.
- Table 1 shows hydrogenated soy lecithin (HSPC, molecular weight: 790) (Lipoid) and cholesterol (Chol, molecular weight 386.65) (Solvay).
- the mixed lipid having the composition shown in Table 1 was prepared by weighing quantitatively, dissolving it in 25 ml of toluene (Kanto Kagaku) heated at 60, cooling with ice, and freeze-drying.
- PEG-PE Polyethylene glycol (molecular weight 5000) -phosphatidylethanolamine (PEG-PE, molecular weight 5938) (Genzyme) as a surface modifier equivalent to 0.75 mo 1% of the total lipid content (Genzyme) (saline solution: 36.74 mg) / ml) and add 1.2 lml, 60. PEG-PE was introduced by heating at C for 30 minutes. Gel filtration removed unencapsulated gemushi hydrochloride bottles.
- Table 1 lists the total lipid composition, lipid component ratio, drug concentration, total lipid, drug / lipid ratio and mass value obtained for the gemcitabine hydrochloride-encapsulated liposomes prepared above, and the particle size measured as follows. Shown in
- the “lipid component ratio” is represented by a molar ratio of lipids (phospholipids and cholesterols in the following examples).
- Total lipid composition indicates the composition of the following “total lipid” in molar ratio.
- Total lipid refers to the cationization of surface modifiers in the case of lipid or cationized lipid membranes
- the total amount of lipid containing the agent is shown in molar concentration (mM).
- PEG derivatives eg, PEG-PE are not included in this total lipid.
- Drug concentration is the concentration of gemushi hydrochloride in the drug carrier dispersion.
- the “drug Z lipid ratio” is a molar ratio between the total lipid concentration and the concentration of gemushi hydrochloride encapsulated in ribosomes.
- Particle size means the average particle size obtained by measuring a drug carrier with a particle size distribution meter (Zetasizer 3000HS, Malvern Instruments). table 1
- the liposomes encapsulated in gemushi bin hydrochloride prepared in Example 1 and Comparative example 1 were diluted in an equivalent amount of a phosphate buffer (pH 7.4) and heated at 37 ° C for 1, 2 and 7 days. Inner ribosome in phosphate buffer After the heating, diluted 4-fold by adding physiological saline, ultracentrifugation (lX 10 5 g, 2 hours, 10 ° C) over a period of, hydrochloride Gemushi evening bottle The sealed liposomes were settled. The drug release rate (%) from the ribosome was calculated by quantifying the amount of gemushi hydrochloride present in the supernatant. The results are shown in Figure 1. (Test Example 2)
- a gemcitabine hydrochloride-encapsulated liposome was prepared in the same manner as in Example 1 except that the mixed lipid (including the cationized lipid) obtained above was used. List the total lipid composition, lipid component ratio, drug concentration, total lipid, drug / lipid ratio and weighed value, and the particle size measured as follows for the liposomes encapsulated in gemushi hydrochloride bottle prepared above. Table 2 shows the results. Table 2
- a ribosome encapsulated in gemushibin hydrochloride was prepared in the same manner as in Example 1.
- Table 3 lists the lipid component ratio, drug concentration, total lipids, drug and umami ratio and weighed value, and the particle size measured as follows.
- TRX-20 3,5-dipentyldecyloxybenzamidine hydrochloride
- Example 2 was repeated except that 3,5-dipentyldecyloxybenzamidine hydrochloride (TRX-20), hydrogenated soybean lecithin (HSPC), and cholesterol (Cho 1) were quantified as shown in Table 4. Similarly, mixed lipids (including cationized J3 umami) having the composition shown in Table 4 were prepared.
- TRX-20 3,5-dipentyldecyloxybenzamidine hydrochloride
- HSPC hydrogenated soybean lecithin
- Cho 1 cholesterol
- mixed lipids including cationized J3 umami
- the liposomes encapsulated in gemushi hydrochloride bottle prepared in Example 4 and Comparative Example 4 were subjected to a stability test in a buffer at 37 ° C. in the same manner as in Test Example 1 above.
- the amount of gemushi bottle was quantified and the drug release rate (%) was calculated.
- Fig. 4 shows the results.
- the stability test was performed on the liposomes encapsulated in gemushi evening bottle prepared in Example 4 and Comparative Example 4 in the presence of 10% fetal serum in a buffer at 37 ° C in the same manner as in Test Example 2 above.
- the amount of gemushi hydrochloride present in the supernatant was quantified, and the drug release rate () was calculated.
- Fig. 5 shows the results.
- the gemcitabine-encapsulated ribosome was prepared in the same manner as in Example 1 except that the drug concentration of gemcitabine hydrochloride shown in Table 5 was used.
- Table 5 lists the total lipid composition, lipid component ratio, drug concentration, total lipid, drug Z lipid ratio and weighed value determined for the gemcitabine hydrochloride-encapsulated liposomes prepared above, and the particle size measured as follows. Show. Table 5
- the concentration of gemushi bin contained in the drug carrier in each plasma was determined according to the high-performance liquid chromatographic method (KB Freeman et.al. J. Chromatogr. B 665 (1995) 171-181). (Hereinafter, the concentration of gemushibin is the concentration of gemushibin contained in the drug carrier in plasma.)
- Fig. 6 shows the results.
- the amount of saline solution (36.74 mgZml) of PEG-PE (surface modifier) to be added to ribosomes was 0.75 mol% of the total lipid amount.
- Gemushi hydrochloride encapsulated ribosomes were prepared in the same manner as in Example 1 except that the amounts were 81 and 1.22 ml.
- the ribosome prepared in Example 6 was injected into a mouse (BALBZc, female, 5-week-old, Japan Chillus) via the tail vein with a dose of 3 mgZkg as a gemushi evening bottle. Blood was collected 1, 6, and 24 hours after injection, and centrifuged (3,000 rpm, 15 minutes, 10 ° C) to collect plasma. The concentration of gemushi bin in each plasma was measured by high performance liquid chromatography (same as in Test Example 6). Fig. 7 shows the results.
- the retention of gemcitabine hydrochloride in the blood of the drug carrier improves, but it becomes more difficult to suppress the release of gemcitabine hydrochloride from the drug carrier. Even when the content of cholesterols is low, the retention rate in blood can be improved by increasing the introduction rate of PEGPE.
- the pharmaceutical carrier of the present invention is obtained by encapsulating gemushibin hydrochloride in a carrier formed of a membrane composed of phospholipids containing cholesterol in a specific amount within the scope of the present invention. It has become possible to provide a stable gemushi bottle formulation capable of suppressing the rate of release of gemushi bottle from a drug carrier. In other words, the release rate of gemushi evening bottle can be suppressed, the local concentration of gemushi evening bottle can be maintained over a long period, and its medicinal effect can be exhibited.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005513558A JPWO2005021012A1 (ja) | 2003-08-29 | 2004-08-30 | ゲムシタビン封入薬剤担体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-209614 | 2003-08-29 | ||
JP2003209614 | 2003-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005021012A1 true WO2005021012A1 (ja) | 2005-03-10 |
Family
ID=34263970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012871 WO2005021012A1 (ja) | 2003-08-29 | 2004-08-30 | ゲムシタビン封入薬剤担体 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005021012A1 (ja) |
WO (1) | WO2005021012A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006273812A (ja) * | 2005-03-30 | 2006-10-12 | Terumo Corp | リポソーム製剤の製造方法 |
JP2012017308A (ja) * | 2010-07-09 | 2012-01-26 | Nipro Corp | ゲムシタビン水溶液製剤 |
WO2013051732A1 (ja) * | 2011-10-07 | 2013-04-11 | 国立大学法人鳥取大学 | リポソーム複合体 |
WO2017078008A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット |
WO2017078009A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
US10646442B2 (en) | 2014-04-30 | 2020-05-12 | Fujifilm Corporation | Liposome composition and method for producing same |
US20210100745A1 (en) * | 2014-04-30 | 2021-04-08 | Fujifilm Corporation | Liposome composition and method for producing same |
WO2023179423A1 (zh) * | 2022-03-25 | 2023-09-28 | 四川科伦药物研究院有限公司 | 一种吉西他滨脂质体药物组合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60215633A (ja) * | 1984-04-11 | 1985-10-29 | Terumo Corp | 腸管吸収性ウロキナ−ゼリポソ−ム組成物 |
JPH04244017A (ja) * | 1991-01-31 | 1992-09-01 | Kyowa Hakko Kogyo Co Ltd | リポソーム製剤 |
JP2000319193A (ja) * | 1999-03-01 | 2000-11-21 | Sumitomo Pharmaceut Co Ltd | 抗がん療法または放射線による組織障害の予防及び/又は治療剤 |
JP2001055343A (ja) * | 1998-11-02 | 2001-02-27 | Terumo Corp | リポソーム |
WO2002030397A1 (es) * | 2000-10-10 | 2002-04-18 | Lipotec, S.A. | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos |
-
2004
- 2004-08-30 JP JP2005513558A patent/JPWO2005021012A1/ja not_active Withdrawn
- 2004-08-30 WO PCT/JP2004/012871 patent/WO2005021012A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60215633A (ja) * | 1984-04-11 | 1985-10-29 | Terumo Corp | 腸管吸収性ウロキナ−ゼリポソ−ム組成物 |
JPH04244017A (ja) * | 1991-01-31 | 1992-09-01 | Kyowa Hakko Kogyo Co Ltd | リポソーム製剤 |
JP2001055343A (ja) * | 1998-11-02 | 2001-02-27 | Terumo Corp | リポソーム |
JP2000319193A (ja) * | 1999-03-01 | 2000-11-21 | Sumitomo Pharmaceut Co Ltd | 抗がん療法または放射線による組織障害の予防及び/又は治療剤 |
WO2002030397A1 (es) * | 2000-10-10 | 2002-04-18 | Lipotec, S.A. | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos |
Non-Patent Citations (1)
Title |
---|
GABIZON A. ET AL.: "Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals", ADVANCED DRUG DELIVERY REVIEWS, vol. 24, 1997, pages 337 - 344, XP002904174 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006273812A (ja) * | 2005-03-30 | 2006-10-12 | Terumo Corp | リポソーム製剤の製造方法 |
JP2012017308A (ja) * | 2010-07-09 | 2012-01-26 | Nipro Corp | ゲムシタビン水溶液製剤 |
WO2013051732A1 (ja) * | 2011-10-07 | 2013-04-11 | 国立大学法人鳥取大学 | リポソーム複合体 |
CN103874482A (zh) * | 2011-10-07 | 2014-06-18 | 国立大学法人鸟取大学 | 脂质体复合物 |
JPWO2013051732A1 (ja) * | 2011-10-07 | 2015-03-30 | 国立大学法人鳥取大学 | リポソーム複合体 |
EP2764861A4 (en) * | 2011-10-07 | 2015-06-17 | Nat Univ Corp Tottori Univ | LIPOSOMVERBUNDKÖRPER |
US9872833B2 (en) | 2011-10-07 | 2018-01-23 | National University Corporation Tottori University | Liposome composite body |
US11684575B2 (en) | 2014-04-30 | 2023-06-27 | Fujifilm Corporation | Liposome composition and method for producing same |
US20210100745A1 (en) * | 2014-04-30 | 2021-04-08 | Fujifilm Corporation | Liposome composition and method for producing same |
US10646442B2 (en) | 2014-04-30 | 2020-05-12 | Fujifilm Corporation | Liposome composition and method for producing same |
US20180243215A1 (en) * | 2015-11-02 | 2018-08-30 | Fujifilm Corporation | Liposome composition and method for producing the same |
WO2017078009A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
JPWO2017078008A1 (ja) * | 2015-11-02 | 2018-08-09 | 富士フイルム株式会社 | ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット |
JP2019178181A (ja) * | 2015-11-02 | 2019-10-17 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
CN108348538A (zh) * | 2015-11-02 | 2018-07-31 | 富士胶片株式会社 | 包含吉西他滨脂质体组合物的肿瘤治疗药及试剂盒 |
CN111437259A (zh) * | 2015-11-02 | 2020-07-24 | 富士胶片株式会社 | 包含吉西他滨或其盐的脂质体组合物 |
CN111632030A (zh) * | 2015-11-02 | 2020-09-08 | 富士胶片株式会社 | 包含吉西他滨或其盐的脂质体组合物的制造方法 |
JPWO2017078009A1 (ja) * | 2015-11-02 | 2018-08-09 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
EP3372232B1 (en) * | 2015-11-02 | 2021-04-14 | FUJIFILM Corporation | Tumor therapeutic agent comprising gemcitabine liposome composition and kit |
US11166914B2 (en) | 2015-11-02 | 2021-11-09 | Fujifilm Corporation | Tumor therapeutic agent and kit containing gemcitabine liposome composition |
US11166913B2 (en) | 2015-11-02 | 2021-11-09 | Fujifilm Corporation | Tumor therapeutic agent and kit containing gemcitabine liposome composition |
RU2761620C2 (ru) * | 2015-11-02 | 2021-12-13 | Фуджифилм Корпорэйшн | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
RU2768178C2 (ru) * | 2015-11-02 | 2022-03-23 | Фуджифилм Корпорэйшн | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
WO2017078008A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット |
WO2023179423A1 (zh) * | 2022-03-25 | 2023-09-28 | 四川科伦药物研究院有限公司 | 一种吉西他滨脂质体药物组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005021012A1 (ja) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100889139B1 (ko) | 이리노테칸 제제 | |
Jadhav et al. | Novel vesicular system: an overview | |
US9655848B2 (en) | Liposomes for in-vivo delivery | |
JP3571335B2 (ja) | リポゾームマイクロレシーバー組成物および方法 | |
Lohumi | A novel drug delivery system: niosomes review | |
US8241663B2 (en) | Liposome preparation | |
KR101132626B1 (ko) | 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법 | |
JP2003530362A (ja) | 診断剤をターゲッティングするための脂質ベースの系 | |
EP3138557B1 (en) | Liposome composition and method for producing same | |
Zhai et al. | Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery | |
Oku et al. | Evaluation of drug targeting strategies and liposomal trafficking. | |
KR100847626B1 (ko) | 수난용성 캄프토테신 함유 리포솜 제제 | |
WO2005021012A1 (ja) | ゲムシタビン封入薬剤担体 | |
US20040062797A1 (en) | Release of therapeutic agents in a vessel or tissue | |
Bangale et al. | Stealth liposomes: a novel approach of targeted drug delivery in cancer therapy | |
JP5110880B2 (ja) | 医薬組成物、製剤および組み合わせ製剤 | |
EP3753549A1 (en) | Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament | |
WO2011037252A1 (ja) | スピカマイシン誘導体を含有するリポソーム製剤 | |
JPWO2003015753A1 (ja) | リポソーム製剤 | |
CN110200920B (zh) | 一种还原敏感药物组合物及其制备和应用 | |
KR100996975B1 (ko) | 혈류 내 순환시간 증가를 위한 단백질로 수식된 리포솜 및이의 제조방법 | |
Paramshetti et al. | In vivo fate of liposomes: Biodistribution and cell membrane interactions | |
WO2014050509A1 (ja) | リポソームおよびリポソーム製剤 | |
KR100768265B1 (ko) | 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법 | |
WO2017110772A1 (ja) | リポソーム及びリポソーム組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513558 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |